Skip to main content
Fig. 1 | BMC Medicine

Fig. 1

From: Combined impact of lipidomic and genetic aberrations on clinical outcomes in metastatic castration-resistant prostate cancer

Fig. 1

Kaplan-Meier analysis according to 3-lipid signature status in the discovery and validation cohorts. Using A radiographic progression-free survival (rPFS) in the discovery cohort, B overall survival (OS) in the discovery cohort, C OS in the taxane subset of the discovery cohort, D OS in the androgen receptor signalling inhibitor (ARSI) subset of the discovery cohort and E OS in the validation cohort

Back to article page

BMC Medicine

ISSN: 1741-7015

Contact us